Eylea is indicated for adults for the treatment of: neovascular (wet) age-related macular degeneration (AMD) (see Pharmacology: Pharmacodynamics under Actions); visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see Pharmacology: Pharmacodynamics under Actions); visual impairment due to diabetic macular oedema (DME) (see Pharmacology: Pharmacodynamics under Actions); visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see Pharmacology: Pharmacodynamics under Actions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
